Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Genentech Inc Drug Patent Portfolio

Genentech Inc owns 5 orange book drugs protected by 64 US patents with Evrysdi having the least patent protection, holding only 5 patents. And Esbriet with maximum patent protection, holding 22 patents. Given below is the list of Genentech Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11925648 Solid dosage form having excellent stability 21 Apr, 2041
Active
US12064438 Pharmaceutical preparation excellent in light stability and dissolution property 09 Oct, 2039
Active
US11534444 Treatment of SMA 04 Oct, 2038
Active
US11261198 Process for preparing substituted polycyclic pyridone derivative and crystal thereof 25 Sep, 2038
Active
US10398693 Pharmaceutical compositions and dosage forms 18 Jul, 2038
Active
US11253515 Pharmaceutical compositions and dosage forms 18 Jul, 2038
Active
US10759814 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
Active
US11306106 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
Active
US10738037 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
Active
US11091469 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
Active
US10188637 Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same 28 Mar, 2037
Active
US10590102 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Dec, 2036
Active
US11254649 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Dec, 2036
Active
US10478400 Immediate-release tablets containing combimetinib and methods of making and using the same 29 Dec, 2036
Active
US11938136 Compositions for treating spinal muscular atrophy 08 Nov, 2036
Active
US10590102 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Jun, 2036
Active
US11254649 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Jun, 2036
Active
US10478400 Immediate-release tablets containing combimetinib and methods of making and using the same 29 Jun, 2036
Active
US10392406 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
Active
US10633397 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
Active
US11827646 Compounds for treating spinal muscular atrophy 25 Jan, 2036
Active
US9969754 Compounds for treating spinal muscular atrophy 11 May, 2035
Active
US10561651 Methods for treating neuroblastoma 19 Feb, 2035
Active
US10231965 Molecules for administration to ROS1 mutant cancer cells 17 Feb, 2035
Active
US11087354 Combination therapies 22 Dec, 2034
Active
US11087354 Combination therapies 22 Jun, 2034
Active
US8778947 Methods of administering pirfenidone therapy 30 Aug, 2033
Active
US9085565 Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
Active
US9649306 Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
Active
US9586955 Compounds for treating spinal muscular atrophy 08 Feb, 2033
Active
US8987441 Substituted polycyclic carbamoyl pyridone derivative prodrug 21 Sep, 2031
Active
US8927710 Substituted polycyclic carbamoylpyridone derivative 05 May, 2031
Active
US9815835 Substituted polycyclic carbamolypyridone derivative 14 Jun, 2030
Active
US7803839 Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 May, 2030
Active
US7816383 Methods of administering pirfenidone therapy 08 Jan, 2030
Active
US7910610 Methods of administering pirfenidone therapy 08 Jan, 2030
Active
US8013002 Methods of administering pirfenidone therapy 08 Jan, 2030
Active
US8084475 Pirfenidone therapy and inducers of cytochrome P450 08 Jan, 2030
Active
US8318780 Methods of administering pirfenidone therapy 08 Jan, 2030
Active
US8648098 Pirfenidone therapy and inducers of cytochrome P450 08 Jan, 2030
Active
US8754109 Pirfenidone therapy and inducers of cytochrome P450 08 Jan, 2030
Active
US7803839 Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 Nov, 2029
Active
US7566729 Modifying pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
Active
US7635707 Pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
Active
US8592462 Pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
Active
US8609701 Pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
Active
US8299057 Substituted indazole derivatives active as kinase inhibitors 01 Mar, 2029
Active
US8673893 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9029356 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9085558 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9255087 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9616059 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US8383150 Granulate formulation of pirfenidone and pharmaceutically acceptable excipients 10 May, 2028
Active
US7696236 Method of providing pirfenidone therapy to a patient 18 Dec, 2027
Active
US7696326 Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof 18 Dec, 2027
Active
US7767700 Method of providing pirfenidone therapy to a patient 18 Dec, 2027
Active
US8420674 Method of providing pirfenidone therapy to a patient 18 Dec, 2027
Active
US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Apr, 2027
Active
US11597699 MEK inhibitors and methods of their use 05 Oct, 2026
Active
US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Oct, 2026
Active
US7767225 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 22 Sep, 2026
Active
US7988994 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 22 Sep, 2026
Active
US8753679 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 22 Sep, 2026
Active
US9561217 Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone 25 Jan, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Genentech Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 17 Jul, 2024 US8362002
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8318780
Payment of Maintenance Fee, 12th Year, Large Entity 30 Apr, 2024 US8299057
Recordation of Patent eGrant 26 Mar, 2024 US11938136
Mail Patent eGrant Notification 26 Mar, 2024 US11938136
Patent Issue Date Used in PTA Calculation
Critical
26 Mar, 2024 US11938136
Patent eGrant Notification 26 Mar, 2024 US11938136
Sequence Moved to Public Database 26 Mar, 2024 US11938136
Email Notification
Critical
26 Mar, 2024 US11938136
Recordation of Patent Grant Mailed
Critical
26 Mar, 2024 US11938136
Email Notification
Critical
12 Mar, 2024 US11925648
Patent eGrant Notification 12 Mar, 2024 US11925648
Patent Issue Date Used in PTA Calculation
Critical
12 Mar, 2024 US11925648
Mail Patent eGrant Notification 12 Mar, 2024 US11925648
Recordation of Patent eGrant 12 Mar, 2024 US11925648


Genentech Inc Drug Patents' Oppositions Filed in EPO

Genentech Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 05, 2012, by Eip Limited. This opposition was filed on patent number EP06825554A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16151564A Mar, 2022 Zentiva k.s. Granted and Under Opposition
EP16151564A Mar, 2022 Generics [UK] Limited Granted and Under Opposition
EP16151564A Mar, 2022 STADA Arzneimittel AG Granted and Under Opposition
EP16151564A Mar, 2022 Aera A/S Granted and Under Opposition
EP17716354A Feb, 2022 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition
EP13176914A Feb, 2021 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP13176914A Feb, 2021 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP13176914A Feb, 2021 Aera A/S Granted and Under Opposition
EP10835207A Feb, 2021 Intas Pharmaceuticals Ltd. Revoked
EP10835207A Feb, 2021 Generics [UK] Limited Revoked
EP10835207A Feb, 2021 SANDOZ AG Revoked
EP13176914A Feb, 2021 SANDOZ AG Granted and Under Opposition
EP10835207A Feb, 2021 Aera A/S Revoked
EP10835207A Jan, 2021 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP10835207A Jan, 2021 STADA Arzneimittel AG Revoked
EP13753131A Mar, 2020 Sandoz AG Opposition rejected
EP13275196A Jun, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP13275196A Jun, 2017 Sandoz AG Revoked
EP11002040A Jan, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP11002040A Jan, 2017 Sandoz AG Revoked
EP12166074A Jan, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP12166074A Dec, 2016 Sandoz AG Revoked
EP11002040A Dec, 2016 ratiopharm GmbH Revoked
EP12166074A Dec, 2016 ratiopharm GmbH Revoked
EP11001414A Jul, 2015 Sandoz AG Revoked
EP06815221A Mar, 2015 Dannenberger, Oliver Andre Patent maintained as amended
EP10250379A Jun, 2012 Sandoz AG Revoked
EP06825554A Jan, 2012 EIP Limited Opposition rejected


Genentech Inc's Family Patents

Genentech Inc drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 20.3% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Genentech Inc Drug List

Given below is the complete list of Genentech Inc's drugs and the patents protecting them.


1. Cotellic

Cotellic is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10590102
(Pediatric)
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Dec, 2036
(12 years from now)
Active
US11254649
(Pediatric)
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Dec, 2036
(12 years from now)
Active
US10478400
(Pediatric)
Immediate-release tablets containing combimetinib and methods of making and using the same 29 Dec, 2036
(12 years from now)
Active
US10590102 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Jun, 2036
(11 years from now)
Active
US11254649 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Jun, 2036
(11 years from now)
Active
US10478400 Immediate-release tablets containing combimetinib and methods of making and using the same 29 Jun, 2036
(11 years from now)
Active
US11087354
(Pediatric)
Combination therapies 22 Dec, 2034
(10 years from now)
Active
US11087354 Combination therapies 22 Jun, 2034
(9 years from now)
Active
US7803839
(Pediatric)
Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 May, 2030
(5 years from now)
Active
US7803839 Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 Nov, 2029
(4 years from now)
Active
US8362002
(Pediatric)
Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Apr, 2027
(2 years from now)
Active
US11597699 MEK inhibitors and methods of their use 05 Oct, 2026
(1 year, 10 months from now)
Active
US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Oct, 2026
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cotellic's drug page


2. Esbriet

Esbriet is protected by 22 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10188637 Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same 28 Mar, 2037
(12 years from now)
Active
US8778947 Methods of administering pirfenidone therapy 30 Aug, 2033
(8 years from now)
Active
US7816383 Methods of administering pirfenidone therapy 08 Jan, 2030
(5 years from now)
Active
US7910610 Methods of administering pirfenidone therapy 08 Jan, 2030
(5 years from now)
Active
US8013002 Methods of administering pirfenidone therapy 08 Jan, 2030
(5 years from now)
Active
US8084475 Pirfenidone therapy and inducers of cytochrome P450 08 Jan, 2030
(5 years from now)
Active
US8318780 Methods of administering pirfenidone therapy 08 Jan, 2030
(5 years from now)
Active
US8648098 Pirfenidone therapy and inducers of cytochrome P450 08 Jan, 2030
(5 years from now)
Active
US8754109 Pirfenidone therapy and inducers of cytochrome P450 08 Jan, 2030
(5 years from now)
Active
US7566729 Modifying pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
(4 years from now)
Active
US7635707 Pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
(4 years from now)
Active
US8592462 Pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
(4 years from now)
Active
US8609701 Pirfenidone treatment for patients with atypical liver function 22 Apr, 2029
(4 years from now)
Active
US8383150 Granulate formulation of pirfenidone and pharmaceutically acceptable excipients 10 May, 2028
(3 years from now)
Active
US7696236 Method of providing pirfenidone therapy to a patient 18 Dec, 2027
(3 years from now)
Active
US7696326 Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof 18 Dec, 2027
(3 years from now)
Active
US7767700 Method of providing pirfenidone therapy to a patient 18 Dec, 2027
(3 years from now)
Active
US8420674 Method of providing pirfenidone therapy to a patient 18 Dec, 2027
(3 years from now)
Active
US7767225 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 22 Sep, 2026
(1 year, 10 months from now)
Active
US7988994 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 22 Sep, 2026
(1 year, 10 months from now)
Active
US8753679 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients 22 Sep, 2026
(1 year, 10 months from now)
Active
US9561217 Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone 25 Jan, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Esbriet's drug page


3. Evrysdi

Evrysdi is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11534444 Treatment of SMA 04 Oct, 2038
(13 years from now)
Active
US11938136 Compositions for treating spinal muscular atrophy 08 Nov, 2036
(11 years from now)
Active
US11827646 Compounds for treating spinal muscular atrophy 25 Jan, 2036
(11 years from now)
Active
US9969754 Compounds for treating spinal muscular atrophy 11 May, 2035
(10 years from now)
Active
US9586955 Compounds for treating spinal muscular atrophy 08 Feb, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evrysdi's drug page


4. Rozlytrek

Rozlytrek is protected by 14 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10398693 Pharmaceutical compositions and dosage forms 18 Jul, 2038
(13 years from now)
Active
US11253515 Pharmaceutical compositions and dosage forms 18 Jul, 2038
(13 years from now)
Active
US10738037 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
(12 years from now)
Active
US11091469 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
(12 years from now)
Active
US10561651 Methods for treating neuroblastoma 19 Feb, 2035
(10 years from now)
Active
US10231965 Molecules for administration to ROS1 mutant cancer cells 17 Feb, 2035
(10 years from now)
Active
US9085565 Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
(8 years from now)
Active
US9649306 Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
(8 years from now)
Active
US8299057 Substituted indazole derivatives active as kinase inhibitors 01 Mar, 2029
(4 years from now)
Active
US8673893 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(3 years from now)
Active
US9029356 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(3 years from now)
Active
US9085558 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(3 years from now)
Active
US9255087 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(3 years from now)
Active
US9616059 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rozlytrek's drug page


5. Xofluza

Xofluza is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11925648 Solid dosage form having excellent stability 21 Apr, 2041
(16 years from now)
Active
US12064438 Pharmaceutical preparation excellent in light stability and dissolution property 09 Oct, 2039
(14 years from now)
Active
US11261198 Process for preparing substituted polycyclic pyridone derivative and crystal thereof 25 Sep, 2038
(13 years from now)
Active
US10759814 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
(12 years from now)
Active
US11306106 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
(12 years from now)
Active
US10392406 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
(11 years from now)
Active
US10633397 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
(11 years from now)
Active
US8987441 Substituted polycyclic carbamoyl pyridone derivative prodrug 21 Sep, 2031
(6 years from now)
Active
US8927710 Substituted polycyclic carbamoylpyridone derivative 05 May, 2031
(6 years from now)
Active
US9815835 Substituted polycyclic carbamolypyridone derivative 14 Jun, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xofluza's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Genentech Inc News

Lilly's Focus on Direct-to-Consumer Marketing for Obesity, Job Cuts, and Interest in Eye Conditions - BioSpace

04 Sep, 2024

Italy initiates antitrust investigation against Novartis, Roche, and other companies for alleged collaboration in postponing ...

06 Jun, 2024

See More